Los Angeles Capital Management LLC Has $2.56 Million Stock Position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Los Angeles Capital Management LLC trimmed its position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 6.5% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 65,940 shares of the specialty pharmaceutical company’s stock after selling 4,586 shares during the quarter. Los Angeles Capital Management LLC owned approximately 0.21% of Collegium Pharmaceutical worth $2,560,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Principal Securities Inc. acquired a new stake in Collegium Pharmaceutical in the fourth quarter worth about $40,000. China Universal Asset Management Co. Ltd. increased its position in Collegium Pharmaceutical by 320.0% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 3,776 shares of the specialty pharmaceutical company’s stock worth $116,000 after purchasing an additional 2,877 shares during the period. Assetmark Inc. increased its position in Collegium Pharmaceutical by 25.5% in the fourth quarter. Assetmark Inc. now owns 5,445 shares of the specialty pharmaceutical company’s stock worth $168,000 after purchasing an additional 1,108 shares during the period. Johnson Investment Counsel Inc. acquired a new stake in Collegium Pharmaceutical in the fourth quarter worth about $257,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its position in Collegium Pharmaceutical by 28.6% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,841 shares of the specialty pharmaceutical company’s stock worth $272,000 after purchasing an additional 1,967 shares during the period.

Analyst Ratings Changes

COLL has been the subject of several analyst reports. StockNews.com lowered Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, May 1st. Piper Sandler lowered Collegium Pharmaceutical from an “overweight” rating to a “neutral” rating and set a $39.00 target price for the company. in a research report on Friday, May 10th. Jefferies Financial Group upgraded Collegium Pharmaceutical from a “hold” rating to a “buy” rating and boosted their target price for the stock from $41.00 to $44.00 in a research report on Friday, June 7th. Needham & Company LLC lowered Collegium Pharmaceutical from a “buy” rating to a “hold” rating in a research report on Friday, May 10th. Finally, Truist Financial boosted their target price on Collegium Pharmaceutical from $37.00 to $40.00 and gave the stock a “buy” rating in a research report on Monday, February 26th. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $40.75.

Insider Buying and Selling at Collegium Pharmaceutical

In other Collegium Pharmaceutical news, CFO Colleen Tupper sold 19,710 shares of the business’s stock in a transaction that occurred on Tuesday, May 28th. The stock was sold at an average price of $34.21, for a total value of $674,279.10. Following the sale, the chief financial officer now owns 130,845 shares in the company, valued at approximately $4,476,207.45. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other Collegium Pharmaceutical news, Director Garen G. Bohlin sold 28,985 shares of the business’s stock in a transaction that occurred on Tuesday, May 14th. The stock was sold at an average price of $32.30, for a total value of $936,215.50. Following the sale, the director now owns 44,775 shares in the company, valued at approximately $1,446,232.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Colleen Tupper sold 19,710 shares of the business’s stock in a transaction that occurred on Tuesday, May 28th. The shares were sold at an average price of $34.21, for a total value of $674,279.10. Following the completion of the sale, the chief financial officer now owns 130,845 shares in the company, valued at approximately $4,476,207.45. The disclosure for this sale can be found here. In the last quarter, insiders have sold 105,502 shares of company stock worth $3,540,796. Corporate insiders own 3.98% of the company’s stock.

Collegium Pharmaceutical Trading Up 0.3 %

NASDAQ:COLL opened at $31.68 on Friday. Collegium Pharmaceutical, Inc. has a fifty-two week low of $20.83 and a fifty-two week high of $40.95. The company has a debt-to-equity ratio of 1.98, a current ratio of 1.21 and a quick ratio of 1.14. The stock has a market capitalization of $1.04 billion, a PE ratio of 13.20 and a beta of 0.96. The business’s 50-day simple moving average is $34.14 and its 200-day simple moving average is $34.12.

Collegium Pharmaceutical (NASDAQ:COLL) last released its quarterly earnings data on Thursday, May 9th. The specialty pharmaceutical company reported $1.32 earnings per share for the quarter, missing the consensus estimate of $1.36 by ($0.04). Collegium Pharmaceutical had a net margin of 16.46% and a return on equity of 104.98%. The business had revenue of $144.92 million for the quarter, compared to the consensus estimate of $147.04 million. Sell-side analysts expect that Collegium Pharmaceutical, Inc. will post 5.57 earnings per share for the current fiscal year.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.